Sage Therapeutics (NASDAQ:SAGE) is reportedly suing Biogen (NASDAQ:BIIB) over enforcement of a standstill agreement in the ...

In a report released today, David Amsellem from Piper Sandler reiterated a Hold rating on Biogen (BIIB – Research Report), with a price target ...

We recently published a list of Jim Cramer Discussed These 10 NASDAQ 100 Stocks Recently. In this article, we are going to ...

Biogen (NASDAQ:BIIB – Get Free Report) had its price target decreased by stock analysts at Wells Fargo & Company from $190.00 ...

ClearBridge Investments, an investment management company, released its “ClearBridge Growth Strategy” fourth quarter 2024 ...

Sage Therapeutics (NASDAQ:SAGE) has confirmed that the Alzheimer’s drug developer Biogen (NASDAQ:BIIB) has offered to buy all ...

Sage Therapeutics Inc. (NASDAQ:SAGE) confirmed that Biogen Inc. (NASDAQ:BIIB) submitted an unsolicited, nonbinding proposal ...

NASDAQ BIIB opened at $141.00 on Thursday. The firm’s fifty day moving average price is $156.24 and its two-hundred day moving average price is $186.11. Biogen Inc. has a 1 year low of $140.87 ...

Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading today, for the February 28th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB ...

View Our Latest Report on Biogen Biogen Trading Down 1.4 % NASDAQ BIIB opened at $141.00 on Thursday. The business has a fifty day simple moving average of $156.24 and a 200 day simple moving ...

Biogen (BIIB) and Eisai's (ESALF) (ESAIY) announce that U.S. FDA agreed to review their subcutaneous form of Alzheimer's ...

On Monday, the FDA accepted Eisai Co., Ltd. (OTC:ESALY) and Biogen Inc’s (NASDAQ:BIIB) Biologics License Application (BLA) ...